Core Viewpoint - The article discusses the listing application of Shenzhen Maikedian Biomedical Technology Co., Ltd. on the Hong Kong Stock Exchange, highlighting its significance in expanding market and research capabilities [1][2]. Company Overview - Maikedian is a global provider of medical solutions, offering a comprehensive product portfolio that meets clinical needs across various healthcare settings. The company has commercialized over 50 life support products, 80 minimally invasive products, and 210 in vitro diagnostic products, with a presence in over 140 countries and regions [4]. Financial Performance - The company has faced losses in recent years, with reported revenues of approximately RMB 917 million, RMB 1.313 billion, RMB 1.399 billion, and RMB 787 million for the six months ending June 30 in 2022, 2023, 2024, and 2025 respectively. The corresponding losses were RMB 226.16 million, RMB 64.51 million, RMB 96.62 million, and RMB 40.97 million [5][7]. Product Segments - In the life support segment, Maikedian has developed innovative products, achieving the top sales ranking in China for infusion workstations from 2018 to 2024 and for enteral nutrition pumps from 2021 to 2024 [6]. - The minimally invasive segment has shown growth, with sales increasing from RMB 38.6 million in 2022 to RMB 58.65 million in 2023, and further to RMB 72.13 million in 2024. The company attributes this growth to an expanded customer base and increased sales volume [8]. - In vitro diagnostic revenue rose from RMB 11.55 million in 2022 to RMB 16.26 million in 2023, and then to RMB 18.4 million in 2024, driven by an expanding product portfolio and market coverage [9].

据港交所9月11日披露，深圳麦科田生物医疗技术股份有限公司(麦科田)向港交所主板提交上市申请 书，摩根士丹利和华泰国际为其联席保荐人。据招股书，麦科田是一家全球医疗解决方案提供商，今年 上半年亏损约4096.8万元人民币。 | | 篇纂]的[編纂]數目 : [編纂]股H股(視乎[編纂] | | --- | --- | | | 獲行使與否而定) | | [編纂]數目 | [編纂]股H股(可予[編纂]) | | [編纂]數目 | :「編纂]股H股(可予[編纂]及 | | | 視乎「編纂」獲行使與否而定） | | 最高[編纂] : | 每股H股[編纂]港元,另加1%經紀 | | | 佣金、0.0027%證監會交易徵費、 | | | 0.00565%聯交所交易費及0.000159 | | | 會財局交易徵費(須於申請時以 | | | 港元繳足,多繳款項可退還) | | 面值 : | 每股H股人民幣1.00元 r 4巨 管 1 | 生命支持方面，麦科田开发了一系列创新的生命支持产品，其中包括，全球首台远程输注控制系统、中 国首个自主研发的多通道输注工作站、与MRI环境兼容的输注工作站、触控式输液泵、触控式注射泵及 触控 ...